MiniMed shares jump 10% on Abbott dual glucose-ketone sensor deal

MiniMed's exclusive integration of Abbott's dual glucose-ketone sensors adds a safety layer to automated insulin delivery that no rival currently offers, potentially shifting the competitive dynamics in the multibillion-dollar insulin pump market.

MiniMed will integrate Abbott's dual glucose-ketone sensors exclusively into its smart dosing systems, adding real-time ketone detection to automated insulin delivery — a feature no competitor currently offers. The sensors, the same size as Abbott's Instinct — described as the world's smallest and thinnest patient-applied sensor — will provide continuous glucose and ketone data directly to MiniMed's intelligent dosing algorithm.

"By integrating dual glucose-ketone monitoring sensors with our MiniMed smart dosing systems, we're adding an additional layer of intelligence and protection," Que Dallara, chief executive officer of MiniMed, said. "Our system is designed to keep people in tight glucose control and minimize DKA risk through smarter, more consistent automation — intervening before it ever becomes an emergency."

Diabetic ketoacidosis accounts for hundreds of thousands of hospitalizations annually in the US and remains the leading cause of death in children and adults under age 58 with type 1 diabetes, according to a 2024 study published in Diabetes Care. Ketones can rise independently of glucose levels, sometimes even when glucose appears in range, which can delay detection of DKA risk. Today, ketone monitoring requires separate finger-stick blood tests or urine strips, often performed only after symptoms have already appeared. Abbott's dual system has received CE Mark and is under FDA review but is not yet cleared for sale in the US.

MMED shares surged 10.1% to $13.54 on the news, adding about $316 million to its $3.45 billion market cap. Trading volume reached 1.06 million shares, 1.56 times the 20-day average of about 678,000, indicating elevated investor interest. The expanded partnership builds on the companies' existing Instinct sensor collaboration and gives MiniMed an exclusive feature that could drive adoption of its 780G automated insulin delivery and Smart MDI systems.

How the Dual Sensors Change the Risk Calculus

The key clinical distinction is that ketone monitoring today is reactive — patients test only after symptoms appear, when intervention is most urgent and outcomes are less certain. Continuous ketone data changes that to a preventive model, with the system alerting users when ketone levels begin rising above a safe threshold, potentially enabling intervention before DKA develops. For MiniMed, this creates a product moat: no competing automated insulin delivery system from Tandem Diabetes Care's Control-IQ or Insulet's Omnipod 5 currently offers integrated continuous ketone monitoring.

Regulatory Path and Market Timeline

Abbott's dual glucose-ketone system has received CE Mark for the European market and is under review by the US Food and Drug Administration. The companies said they expect to provide further updates on regulatory and commercialization milestones in the coming months. MiniMed's 780G system is already approved for use in children ages 2 to 6 with caregiver supervision, and the dual sensors would be indicated for the same user populations — including those with type 1 or insulin-requiring type 2 diabetes.

Investment Angle

The exclusive arrangement strengthens MiniMed's competitive position in the automated insulin delivery market at a time when rivals are also expanding their sensor partnerships. Tandem Diabetes Care uses Dexcom's G7 continuous glucose monitor, while Insulet's Omnipod 5 works with both Dexcom and Abbott's FreeStyle Libre. By securing exclusive access to Abbott's dual glucose-ketone technology, MiniMed gains a differentiated safety feature that could sway prescribing decisions among endocrinologists and patients concerned about DKA risk. MMED, which trades at about 13 times trailing earnings following the 10% surge, still sits about 40% below its 52-week high, suggesting room for further upside if regulatory clearance and commercial adoption materialize.

This article is for informational purposes only and does not constitute investment advice.